Menlo Park, United States
Hexagon Bio is a biopharma company founded in 2016 and based in the United States. The company is focused on discovering novel medicines in the global metagenome and bringing them to patients. Utilizing a data-driven approach, Hexagon Bio develops targeted small molecule therapeutics by integrating data science, genomics, synthetic biology, chemistry, and automation. Their proprietary platform enables the discovery of potent, evolutionarily-refined small molecules and their cognate targets directly from DNA sequences.
With a specific emphasis on mining fungal genomes, Hexagon Bio is dedicated to inspiring the next generation of targeted therapies for diseases with unmet needs. In their most recent funding round in October 2022, the company secured a substantial $77.30M Series B investment. The investors in this round included Two Sigma Ventures, 8VC, The Column Group, ATEL Capital, Nextech Invest, and Canada Pension Plan Investment Board.
The innovative and multi-disciplinary approach of Hexagon Bio positions it at the forefront of biotechnology and healthcare industries, offering promising potential for addressing unmet medical needs and advancing the discovery of transformative medicines.
Maad
